凯普生物(300639) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥693,008,112.93, representing a 68.50% increase year-over-year[4] - Net profit attributable to shareholders was ¥255,901,368.29, up 77.33% compared to the same period last year[4] - The net profit after deducting non-recurring gains and losses was ¥247,329,518.28, reflecting a 76.49% increase year-over-year[4] - The company achieved a revenue of CNY 1,991.64 million for the first three quarters of 2021, representing a year-on-year growth of 117.23%[18] - The net profit attributable to shareholders for the same period was CNY 646.92 million, an increase of 136.71% year-on-year[18] - In Q3 2021, the company reported a revenue of CNY 693.01 million, reflecting a year-on-year growth of 68.50%[18] - The net profit attributable to shareholders in Q3 2021 was CNY 255.90 million, up 77.33% compared to the same quarter last year[18] - The net profit for Q3 2021 was CNY 683,488,650.53, a significant increase of 128.5% compared to CNY 299,415,923.83 in Q3 2020[28] - The total profit for Q3 2021 was CNY 809,490,780.85, a substantial increase of 130.0% from CNY 352,062,786.73 in Q3 2020[28] - The total revenue from operating activities reached CNY 1,483,641,261.22, up from CNY 748,276,022.72 in the same period last year, indicating a growth of 98.2%[31] Assets and Liabilities - Total assets as of September 30, 2021, amounted to ¥3,947,055,007.07, a 38.16% increase from the end of the previous year[4] - Total current assets amounted to ¥1,962,126,206.56 as of December 31, 2020[34] - Non-current assets totaled ¥894,838,066.14, contributing to a total asset value of ¥2,856,964,272.70[35] - Total current liabilities reached ¥303,021,737.91, with short-term borrowings at ¥75,272,240.00 and accounts payable at ¥86,199,861.84[36] - Total liabilities were reported at ¥322,685,997.69, while total equity stood at ¥2,534,278,275.01[36] Cash Flow - The operating cash flow for the year-to-date period was ¥258,782,373.78, showing a 113.07% increase[4] - Cash received from sales and services increased by 103.94% to CNY 1,468.81 million, driven by higher operating income[12] - The company's cash outflow for purchasing goods and services rose by 182.92% to CNY 602.11 million, reflecting increased procurement of products and raw materials[12] - The cash flow from operating activities generated a net amount of CNY 258,782,373.78, compared to CNY 121,454,522.72 in the previous year, marking a growth of 112.7%[31] - Investment activities resulted in a net cash outflow of CNY 204,577,712.64, an improvement from a net outflow of CNY 271,693,295.44 in the same period last year[31] - The cash and cash equivalents at the end of the period stood at CNY 557,855,554.71, down from CNY 1,170,439,588.04 at the end of Q3 2020[32] Expenses - Research and development expenses increased by 84.52% to CNY 80.12 million due to higher salaries and materials costs[11] - Sales expenses rose by 31.15% to CNY 269.28 million, primarily due to increased marketing costs associated with revenue growth[11] - The company has invested heavily in R&D, with expenses amounting to CNY 80,124,533.38 for the current period, compared to CNY 43,422,241.05 in the previous period[27] Investments and Expansion - The company has made a 100% investment in Guangzhou Yingzan Biotechnology Co., Ltd., reflecting its strategy for market expansion[9] - The company has established multiple R&D innovation platforms, including a provincial-level HPV-related disease molecular diagnostic engineering technology research center and a postdoctoral research workstation[19] - The company has accelerated the construction of third-party medical laboratories, establishing 35 laboratories across various cities, with 24 already obtaining medical institution practice licenses[20] - The company has established a nationwide third-party testing service network, gradually forming a comprehensive service capability[20] Recognition and Innovation - The company has been recognized as a "National Technology Innovation Demonstration Enterprise" by the Ministry of Industry and Information Technology, which is expected to positively impact future innovation[19] - As of now, the company has obtained a total of 71 patent certificates, including 34 invention patents, and has registered 69 medical device products, with 23 classified as Class III medical devices[19] Other Information - The company reported an investment income of CNY 138.03 million, a significant increase of 273.96% attributed to higher financial management returns[11] - The company reported an increase in investment income to CNY 13,802,611.54 from CNY 3,690,964.07, which is a growth of 274.5%[28] - The company has implemented new leasing standards effective January 1, 2021, without impacting prior financial results[37] - The report for the third quarter of 2021 was not audited, indicating a preliminary financial status[39]